ArticleThe Journal of clinical investigation2026

XY0206: A promising sunitinib-derived FLT3 inhibitor targeting therapy-resistant acute myeloid leukemia.

Yiping YangPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.